Celgene Corporation (CELG)

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. The company offers ABRAXANE, a paclitaxel powder for injectable suspension nanoparticle; IDHIFA that are enasidenib tablets; INREBIC, which are fedratinib capsules; ISTODAX, a lyophilized powder for injection; ONUREG that are azacitidine tablets; POMALYST, pomalidomide capsules; REBLOZYL, an injection for luspatercept; REVLIMID that are lenalidomide capsules; THALOMID, which are thalidomide capsules; VIDAZA, an injection of azacytidine; and ZEPOSIA that are ozanimod capsules. It provides pharmaceuticals in the areas of oncology, hematology, immunoscience, cardiovascular disease, and fibrosis. The company was incorporated in 1986 and is based in Summit, New Jersey. Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.